Review



bronchial epithelial cell growth medium  (PromoCell)


Bioz Verified Symbol PromoCell is a verified supplier
Bioz Manufacturer Symbol PromoCell manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 96
      Buy from Supplier

    Structured Review

    PromoCell bronchial epithelial cell growth medium
    SARS-CoV-2 opsonized with CL-11 drives increased infectivity of respiratory <t>epithelial</t> cells. ( A and B ), Enhancement of BEAS-2B cell infection with SARS-CoV-2 variants pretreated with rCL-11 (0.1, 1.0, and 10.0 µg/mL) or media for 1 h at 37 °C. ( A ) England/02/2020 (MOI 0.005) and ( B ) B.1.617.2 (MOI 0.05). ( C and D ), Enhancement of Calu-3 cell infection with SARS-CoV-2 variants pretreated with rCL-11 (0.1, 1.0, and 10.0 µg/mL) or media for 1 h at 37 °C. ( C ) England/02/2020 (MOI 0.05) and ( D ) B.1.617.2 (MOI 0.05). Virus titers in the supernatant after 24 h determined by plaque assay. Data are pooled from two ( A , C , D ) or three ( B ) independent experiments and represent the mean ± SEM of triplicate or quadruplicate biological samples. Each group compared to 0 µg/mL rCL-11 by one-way ANOVA with Dunnett’s multiple comparison test, * P < 0.05, and *** P < 0.001. ( E and F ), Representative images of crystal violet stained plaque assay plates of BEAS-2B or Calu-3 cells infected with either England/02/2020 ( E ) or B.1.617.2 ( F ) or opsonized with 10 mg/mL rCL-11. ( G ) L-fucose inhibits the enhancement of SARS-CoV-2 (England/02/2020) infectivity driven by CL-11 in BEAS-2B cells. England/02/2020 (MOI 0.05) pretreated with media or with rCL-11 (10.0 µg/mL) in the presence or absence of L-fucose or D-galactose (1- or 10 mM final concentration) and virus titers determined as above. ( H ) Infectivity of SARS-CoV-2 (England/02/2020) opsonized with CL-11 is not inhibited by NHS. Quantification of SARS-CoV-2 England/02/2020 in the supernatant of BEAS-2B cells 24 h after infection with virus (MOI 0.005) pretreated with media or with rCL-11 (10.0 µg/mL) spiked with or without 10% NHS as detailed above. ( G and H ) Data are representative of two independent experiments with the mean ± SEM of five ( G ) and at least six ( H ) biological samples. ** P < 0.01 and *** P < 0.001 determined by one-way ANOVA with Tukey’s multiple comparison test.
    Bronchial Epithelial Cell Growth Medium, supplied by PromoCell, used in various techniques. Bioz Stars score: 96/100, based on 256 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/bronchial+epithelial+cell+growth+medium/Airway+Epithelial+Cell+Growth+Medium/pmc12582335-184-50-55
    Average 96 stars, based on 256 article reviews
    bronchial epithelial cell growth medium - by Bioz Stars, 2026-10
    96/100 stars

    Images

    1) Product Images from "Glycan recognition by collectin-11 drives SARS-CoV-2 infectivity and membrane injury of respiratory epithelial cells"

    Article Title: Glycan recognition by collectin-11 drives SARS-CoV-2 infectivity and membrane injury of respiratory epithelial cells

    Journal: Proceedings of the National Academy of Sciences of the United States of America

    doi: 10.1073/pnas.2521209122

    SARS-CoV-2 opsonized with CL-11 drives increased infectivity of respiratory epithelial cells. ( A and B ), Enhancement of BEAS-2B cell infection with SARS-CoV-2 variants pretreated with rCL-11 (0.1, 1.0, and 10.0 µg/mL) or media for 1 h at 37 °C. ( A ) England/02/2020 (MOI 0.005) and ( B ) B.1.617.2 (MOI 0.05). ( C and D ), Enhancement of Calu-3 cell infection with SARS-CoV-2 variants pretreated with rCL-11 (0.1, 1.0, and 10.0 µg/mL) or media for 1 h at 37 °C. ( C ) England/02/2020 (MOI 0.05) and ( D ) B.1.617.2 (MOI 0.05). Virus titers in the supernatant after 24 h determined by plaque assay. Data are pooled from two ( A , C , D ) or three ( B ) independent experiments and represent the mean ± SEM of triplicate or quadruplicate biological samples. Each group compared to 0 µg/mL rCL-11 by one-way ANOVA with Dunnett’s multiple comparison test, * P < 0.05, and *** P < 0.001. ( E and F ), Representative images of crystal violet stained plaque assay plates of BEAS-2B or Calu-3 cells infected with either England/02/2020 ( E ) or B.1.617.2 ( F ) or opsonized with 10 mg/mL rCL-11. ( G ) L-fucose inhibits the enhancement of SARS-CoV-2 (England/02/2020) infectivity driven by CL-11 in BEAS-2B cells. England/02/2020 (MOI 0.05) pretreated with media or with rCL-11 (10.0 µg/mL) in the presence or absence of L-fucose or D-galactose (1- or 10 mM final concentration) and virus titers determined as above. ( H ) Infectivity of SARS-CoV-2 (England/02/2020) opsonized with CL-11 is not inhibited by NHS. Quantification of SARS-CoV-2 England/02/2020 in the supernatant of BEAS-2B cells 24 h after infection with virus (MOI 0.005) pretreated with media or with rCL-11 (10.0 µg/mL) spiked with or without 10% NHS as detailed above. ( G and H ) Data are representative of two independent experiments with the mean ± SEM of five ( G ) and at least six ( H ) biological samples. ** P < 0.01 and *** P < 0.001 determined by one-way ANOVA with Tukey’s multiple comparison test.
    Figure Legend Snippet: SARS-CoV-2 opsonized with CL-11 drives increased infectivity of respiratory epithelial cells. ( A and B ), Enhancement of BEAS-2B cell infection with SARS-CoV-2 variants pretreated with rCL-11 (0.1, 1.0, and 10.0 µg/mL) or media for 1 h at 37 °C. ( A ) England/02/2020 (MOI 0.005) and ( B ) B.1.617.2 (MOI 0.05). ( C and D ), Enhancement of Calu-3 cell infection with SARS-CoV-2 variants pretreated with rCL-11 (0.1, 1.0, and 10.0 µg/mL) or media for 1 h at 37 °C. ( C ) England/02/2020 (MOI 0.05) and ( D ) B.1.617.2 (MOI 0.05). Virus titers in the supernatant after 24 h determined by plaque assay. Data are pooled from two ( A , C , D ) or three ( B ) independent experiments and represent the mean ± SEM of triplicate or quadruplicate biological samples. Each group compared to 0 µg/mL rCL-11 by one-way ANOVA with Dunnett’s multiple comparison test, * P < 0.05, and *** P < 0.001. ( E and F ), Representative images of crystal violet stained plaque assay plates of BEAS-2B or Calu-3 cells infected with either England/02/2020 ( E ) or B.1.617.2 ( F ) or opsonized with 10 mg/mL rCL-11. ( G ) L-fucose inhibits the enhancement of SARS-CoV-2 (England/02/2020) infectivity driven by CL-11 in BEAS-2B cells. England/02/2020 (MOI 0.05) pretreated with media or with rCL-11 (10.0 µg/mL) in the presence or absence of L-fucose or D-galactose (1- or 10 mM final concentration) and virus titers determined as above. ( H ) Infectivity of SARS-CoV-2 (England/02/2020) opsonized with CL-11 is not inhibited by NHS. Quantification of SARS-CoV-2 England/02/2020 in the supernatant of BEAS-2B cells 24 h after infection with virus (MOI 0.005) pretreated with media or with rCL-11 (10.0 µg/mL) spiked with or without 10% NHS as detailed above. ( G and H ) Data are representative of two independent experiments with the mean ± SEM of five ( G ) and at least six ( H ) biological samples. ** P < 0.01 and *** P < 0.001 determined by one-way ANOVA with Tukey’s multiple comparison test.

    Techniques Used: Infection, Virus, Plaque Assay, Comparison, Staining, Concentration Assay

    Related Articles

    Transferring:

    Article Title: Curcumin and Other Polyphenolic Compounds in Head and Neck Cancer Chemoprevention
    Article Snippet: Bottoms of wells were coated with 30 mL 0.75% Agar Noble (DIFCO, Detroit, USA) dissolved in 30 mL Dulbecco's modified eagle medium (DMEM), 6 mL 10% fetal calf serum (Gibco), 75 μ L nonessential amino acids (Gibco), 240 μ L penicillin-streptomycin (Sigma Aldrich, Steinheim, Germany), and 120 μ L amphotericin B (Gibco), thus preventing adhesion to the surface. .. Cultures were now covered with 250 μ L Bronchial Epithelial Cell Growth Medium (BEGM, supplemented with Bovine Pituitary Extract, insulin, hydrocortisone, epinephrine, triodothyronine, transferring, and retinoic acid; Promocell; Heidelberg, Germany) per well. ..

    Cell Culture:

    Article Title: NKG2D-dependent effector function of bronchial epithelium-activated alloreactive T-cells.
    Article Snippet: .. In brief, human PBECs from healthy volunteers were obtained during bronchoscopy and cultured in serum-free bronchial epithelial cell growth medium (Promocell, Heidelberg, Germany) containing 100 U?mL-1 penicillin G, 100 mg?mL-1 streptomycin and 0.25 mg?mL-1 amphotericin-B (Invitrogen, Karlsruhe, Germany). ..

    Article Title: Glycan recognition by collectin-11 drives SARS-CoV-2 infectivity and membrane injury of respiratory epithelial cells.
    Article Snippet: .. Donor 1: female, 62 y, Caucasian Donor 2: male, 71 y, Caucasian Donor 3: male, 62 y, Caucasian Cryopreserved HBECs from healthy donors obtained from Epithelix and PromoCell were expanded and then seeded (2.12 × 105 cells/cm2) onto collagen coated (30 μg/mL) tranwells and cultured submerged in Bronchial Epithelial Cell Growth Medium (Promocell) until confluent. .. Cells were then air- lifted and maintained with biweekly refeeding in differentiation medium (PromoCell) for 3 to 4 wk until beating ciliated cells and mucus were observed.

    Article Title: Glycan recognition by collectin-11 drives SARS-CoV-2 infectivity and membrane injury of respiratory epithelial cells
    Article Snippet: .. Donor 1: female, 62 y, Caucasian Donor 2: male, 71 y, Caucasian Donor 3: male, 62 y, Caucasian Cryopreserved HBECs from healthy donors obtained from Epithelix and PromoCell were expanded and then seeded (2.12 × 10 5 cells/cm 2 ) onto collagen coated (30 μg/mL) tranwells and cultured submerged in Bronchial Epithelial Cell Growth Medium (Promocell) until confluent. .. Cells were then air-lifted and maintained with biweekly refeeding in differentiation medium (PromoCell) for 3 to 4 wk until beating ciliated cells and mucus were observed.

    Incubation:

    Article Title: Cytotoxic and Genotoxic Effects of Electronic Cigarette Liquids on Human Mucosal Tissue Cultures of the Oropharynx
    Article Snippet: The popularity of electronic cigarettes (ECs) is rapidly growing and ECs are claimed to be an uncritically regarded alternative to conventional cigarettes.. The mucosal tissue of the upper aerodigestive tract (UADT) is the first contact organ for xenobiotics such as liquids of ECs.. The aim of this study is to investigate the bimolecular effects of e-liquids on human pharyngeal tissue cultures to evaluate whether e-liquids and their components present a risk factor for head and neck squamous cell carcinoma.

    Recombinant:

    Article Title: Expression of CXC chemokine receptors 1 and 2 in human bronchial epithelial cells.
    Article Snippet: Introduction: CXC chemokine receptor 1 (CXCR1) and CXC chemokine receptor 2 (CXCR2) have been shown to play an important role in transepithelial migration of neutrophil granulocytes during inflammation in various tissues.. This study investigated the regulation of gene expression and surface expression of CXCR1 and CXCR2 in a human bronchial epithelial cell line (BEAS-2B), as well as in primary bronchial epithelial cells (PBECs) from 10 COPD patients and 10 control subjects.. Methods and results: The transcription expression of CXCR1 and CXCR2 was quantitatively assessed by means of real-time polymerase chain reaction (PCR) under various inflammatory conditions.

    Article Title: Bronchoepithelial expression of CXCR1 and CXCR2 does not facilitate transepithelial migration of neutrophils.
    Article Snippet: .. Cells were resuspended in serum-free bronchial epithelial cell growth medium (Promocell, Freiburg, Germany) supplemented with a variety of growth factors, including bovine pituitary extract (0.052 mg/ml), recombinant human epidermal growth factor (0.5 ng/ml), insulin (5 g/ ml), hydrocortisone (0.5 g/ml), epinephrine (0.5 g/ml), triiodothyronine (6.5 ng/ml), transferrin (0.01 mg/ml) and retinoic acid (0.1 ng/ml). .. In addition, the medium contained penicillin G (100 U/ml), streptomycin (100 g/ml) and amphotericin B (0.25 g/ml; Invitrogen, Darmstadt, Germany).



    Similar Products

    airway epithelial cell basal medium plus bronchial epithelial cell growth kit  (ATCC)
    96
    ATCC airway epithelial cell basal medium plus bronchial epithelial cell growth kit
    Airway Epithelial Cell Basal Medium Plus Bronchial Epithelial Cell Growth Kit, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/bronchial+epithelial+cell+growth+medium/Bronchial+Epithelial+Cell+Growth+Kit/pm42276073-406-10-21
    Average 96 stars, based on 1 article reviews
    airway epithelial cell basal medium plus bronchial epithelial cell growth kit - by Bioz Stars, 2026-10
    96/100 stars
    		  Buy from Supplier
    bronchial epithelial cell growth medium  (PromoCell)
    96
    PromoCell bronchial epithelial cell growth medium
    SARS-CoV-2 opsonized with CL-11 drives increased infectivity of respiratory <t>epithelial</t> cells. ( A and B ), Enhancement of BEAS-2B cell infection with SARS-CoV-2 variants pretreated with rCL-11 (0.1, 1.0, and 10.0 µg/mL) or media for 1 h at 37 °C. ( A ) England/02/2020 (MOI 0.005) and ( B ) B.1.617.2 (MOI 0.05). ( C and D ), Enhancement of Calu-3 cell infection with SARS-CoV-2 variants pretreated with rCL-11 (0.1, 1.0, and 10.0 µg/mL) or media for 1 h at 37 °C. ( C ) England/02/2020 (MOI 0.05) and ( D ) B.1.617.2 (MOI 0.05). Virus titers in the supernatant after 24 h determined by plaque assay. Data are pooled from two ( A , C , D ) or three ( B ) independent experiments and represent the mean ± SEM of triplicate or quadruplicate biological samples. Each group compared to 0 µg/mL rCL-11 by one-way ANOVA with Dunnett’s multiple comparison test, * P < 0.05, and *** P < 0.001. ( E and F ), Representative images of crystal violet stained plaque assay plates of BEAS-2B or Calu-3 cells infected with either England/02/2020 ( E ) or B.1.617.2 ( F ) or opsonized with 10 mg/mL rCL-11. ( G ) L-fucose inhibits the enhancement of SARS-CoV-2 (England/02/2020) infectivity driven by CL-11 in BEAS-2B cells. England/02/2020 (MOI 0.05) pretreated with media or with rCL-11 (10.0 µg/mL) in the presence or absence of L-fucose or D-galactose (1- or 10 mM final concentration) and virus titers determined as above. ( H ) Infectivity of SARS-CoV-2 (England/02/2020) opsonized with CL-11 is not inhibited by NHS. Quantification of SARS-CoV-2 England/02/2020 in the supernatant of BEAS-2B cells 24 h after infection with virus (MOI 0.005) pretreated with media or with rCL-11 (10.0 µg/mL) spiked with or without 10% NHS as detailed above. ( G and H ) Data are representative of two independent experiments with the mean ± SEM of five ( G ) and at least six ( H ) biological samples. ** P < 0.01 and *** P < 0.001 determined by one-way ANOVA with Tukey’s multiple comparison test.
    Bronchial Epithelial Cell Growth Medium, supplied by PromoCell, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/bronchial+epithelial+cell+growth+medium/Airway+Epithelial+Cell+Growth+Medium/pmc12582335-184-50-55
    Average 96 stars, based on 1 article reviews
    bronchial epithelial cell growth medium - by Bioz Stars, 2026-10
    96/100 stars
    		  Buy from Supplier
    hbepc htepc growth medium  (Cell Applications Inc)
    93
    Cell Applications Inc hbepc htepc growth medium
    SARS-CoV-2 opsonized with CL-11 drives increased infectivity of respiratory <t>epithelial</t> cells. ( A and B ), Enhancement of BEAS-2B cell infection with SARS-CoV-2 variants pretreated with rCL-11 (0.1, 1.0, and 10.0 µg/mL) or media for 1 h at 37 °C. ( A ) England/02/2020 (MOI 0.005) and ( B ) B.1.617.2 (MOI 0.05). ( C and D ), Enhancement of Calu-3 cell infection with SARS-CoV-2 variants pretreated with rCL-11 (0.1, 1.0, and 10.0 µg/mL) or media for 1 h at 37 °C. ( C ) England/02/2020 (MOI 0.05) and ( D ) B.1.617.2 (MOI 0.05). Virus titers in the supernatant after 24 h determined by plaque assay. Data are pooled from two ( A , C , D ) or three ( B ) independent experiments and represent the mean ± SEM of triplicate or quadruplicate biological samples. Each group compared to 0 µg/mL rCL-11 by one-way ANOVA with Dunnett’s multiple comparison test, * P < 0.05, and *** P < 0.001. ( E and F ), Representative images of crystal violet stained plaque assay plates of BEAS-2B or Calu-3 cells infected with either England/02/2020 ( E ) or B.1.617.2 ( F ) or opsonized with 10 mg/mL rCL-11. ( G ) L-fucose inhibits the enhancement of SARS-CoV-2 (England/02/2020) infectivity driven by CL-11 in BEAS-2B cells. England/02/2020 (MOI 0.05) pretreated with media or with rCL-11 (10.0 µg/mL) in the presence or absence of L-fucose or D-galactose (1- or 10 mM final concentration) and virus titers determined as above. ( H ) Infectivity of SARS-CoV-2 (England/02/2020) opsonized with CL-11 is not inhibited by NHS. Quantification of SARS-CoV-2 England/02/2020 in the supernatant of BEAS-2B cells 24 h after infection with virus (MOI 0.005) pretreated with media or with rCL-11 (10.0 µg/mL) spiked with or without 10% NHS as detailed above. ( G and H ) Data are representative of two independent experiments with the mean ± SEM of five ( G ) and at least six ( H ) biological samples. ** P < 0.01 and *** P < 0.001 determined by one-way ANOVA with Tukey’s multiple comparison test.
    Hbepc Htepc Growth Medium, supplied by Cell Applications Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/bronchial+epithelial+cell+growth+medium/Human+Bronchial%2FTracheal+Epithelial+Cell+Media/pmc12907143-197-18-21
    Average 93 stars, based on 1 article reviews
    hbepc htepc growth medium - by Bioz Stars, 2026-10
    93/100 stars
    		  Buy from Supplier
    begm bronchial epithelial cell growth medium bulletkit  (Lonza)
    90
    Lonza begm bronchial epithelial cell growth medium bulletkit
    SARS-CoV-2 opsonized with CL-11 drives increased infectivity of respiratory <t>epithelial</t> cells. ( A and B ), Enhancement of BEAS-2B cell infection with SARS-CoV-2 variants pretreated with rCL-11 (0.1, 1.0, and 10.0 µg/mL) or media for 1 h at 37 °C. ( A ) England/02/2020 (MOI 0.005) and ( B ) B.1.617.2 (MOI 0.05). ( C and D ), Enhancement of Calu-3 cell infection with SARS-CoV-2 variants pretreated with rCL-11 (0.1, 1.0, and 10.0 µg/mL) or media for 1 h at 37 °C. ( C ) England/02/2020 (MOI 0.05) and ( D ) B.1.617.2 (MOI 0.05). Virus titers in the supernatant after 24 h determined by plaque assay. Data are pooled from two ( A , C , D ) or three ( B ) independent experiments and represent the mean ± SEM of triplicate or quadruplicate biological samples. Each group compared to 0 µg/mL rCL-11 by one-way ANOVA with Dunnett’s multiple comparison test, * P < 0.05, and *** P < 0.001. ( E and F ), Representative images of crystal violet stained plaque assay plates of BEAS-2B or Calu-3 cells infected with either England/02/2020 ( E ) or B.1.617.2 ( F ) or opsonized with 10 mg/mL rCL-11. ( G ) L-fucose inhibits the enhancement of SARS-CoV-2 (England/02/2020) infectivity driven by CL-11 in BEAS-2B cells. England/02/2020 (MOI 0.05) pretreated with media or with rCL-11 (10.0 µg/mL) in the presence or absence of L-fucose or D-galactose (1- or 10 mM final concentration) and virus titers determined as above. ( H ) Infectivity of SARS-CoV-2 (England/02/2020) opsonized with CL-11 is not inhibited by NHS. Quantification of SARS-CoV-2 England/02/2020 in the supernatant of BEAS-2B cells 24 h after infection with virus (MOI 0.005) pretreated with media or with rCL-11 (10.0 µg/mL) spiked with or without 10% NHS as detailed above. ( G and H ) Data are representative of two independent experiments with the mean ± SEM of five ( G ) and at least six ( H ) biological samples. ** P < 0.01 and *** P < 0.001 determined by one-way ANOVA with Tukey’s multiple comparison test.
    Begm Bronchial Epithelial Cell Growth Medium Bulletkit, supplied by Lonza, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/bronchial+epithelial+cell+growth+medium/bronchial+epithelial+growth+medium/pmc12281032-244-8-16
    Average 90 stars, based on 1 article reviews
    begm bronchial epithelial cell growth medium bulletkit - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    begm bronchial epithelial cell growth medium bulletkit cc-3170  (Lonza)
    90
    Lonza begm bronchial epithelial cell growth medium bulletkit cc-3170
    SARS-CoV-2 opsonized with CL-11 drives increased infectivity of respiratory <t>epithelial</t> cells. ( A and B ), Enhancement of BEAS-2B cell infection with SARS-CoV-2 variants pretreated with rCL-11 (0.1, 1.0, and 10.0 µg/mL) or media for 1 h at 37 °C. ( A ) England/02/2020 (MOI 0.005) and ( B ) B.1.617.2 (MOI 0.05). ( C and D ), Enhancement of Calu-3 cell infection with SARS-CoV-2 variants pretreated with rCL-11 (0.1, 1.0, and 10.0 µg/mL) or media for 1 h at 37 °C. ( C ) England/02/2020 (MOI 0.05) and ( D ) B.1.617.2 (MOI 0.05). Virus titers in the supernatant after 24 h determined by plaque assay. Data are pooled from two ( A , C , D ) or three ( B ) independent experiments and represent the mean ± SEM of triplicate or quadruplicate biological samples. Each group compared to 0 µg/mL rCL-11 by one-way ANOVA with Dunnett’s multiple comparison test, * P < 0.05, and *** P < 0.001. ( E and F ), Representative images of crystal violet stained plaque assay plates of BEAS-2B or Calu-3 cells infected with either England/02/2020 ( E ) or B.1.617.2 ( F ) or opsonized with 10 mg/mL rCL-11. ( G ) L-fucose inhibits the enhancement of SARS-CoV-2 (England/02/2020) infectivity driven by CL-11 in BEAS-2B cells. England/02/2020 (MOI 0.05) pretreated with media or with rCL-11 (10.0 µg/mL) in the presence or absence of L-fucose or D-galactose (1- or 10 mM final concentration) and virus titers determined as above. ( H ) Infectivity of SARS-CoV-2 (England/02/2020) opsonized with CL-11 is not inhibited by NHS. Quantification of SARS-CoV-2 England/02/2020 in the supernatant of BEAS-2B cells 24 h after infection with virus (MOI 0.005) pretreated with media or with rCL-11 (10.0 µg/mL) spiked with or without 10% NHS as detailed above. ( G and H ) Data are representative of two independent experiments with the mean ± SEM of five ( G ) and at least six ( H ) biological samples. ** P < 0.01 and *** P < 0.001 determined by one-way ANOVA with Tukey’s multiple comparison test.
    Begm Bronchial Epithelial Cell Growth Medium Bulletkit Cc 3170, supplied by Lonza, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/bronchial+epithelial+cell+growth+medium/bronchial+epithelial+growth+medium/10__1016_slash_j__optlastec__2025__113151-74-4-12
    Average 90 stars, based on 1 article reviews
    begm bronchial epithelial cell growth medium bulletkit cc-3170 - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    bronchial epithelial cell growth medium  (Lonza)
    90
    Lonza bronchial epithelial cell growth medium
    miR-488-3p overexpression inhibits LSCC cell proliferation, migration, invasion and <t>epithelial-mesenchymal</t> transition. (A) Quantitative PCR analysis of miR-488-3p expression in LSCC cells transfected with miR-488-3p or NC mimics. (B) Cell Counting Kit-8 and (C) colony formation assays detected the proliferative ability of LSCC cells transfected with miR-488-3p or NC mimics. Transwell assays determined the (D) migration and (E) invasion of LSCC cells transfected with miR-488-3p or NC mimics. (F) Western blotting of the protein levels of E-cadherin, N-cadherin and vimentin. Cropped images represent different blots, but samples are from the same experiment and the blots were processed in parallel. Scale bars, 100 µ m. * P<0.05, ** P<0.01 and *** P<0.001. miR, microRNA; LSCC, laryngeal squamous cell carcinoma; NC, negative control.
    Bronchial Epithelial Cell Growth Medium, supplied by Lonza, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/bronchial+epithelial+cell+growth+medium/bronchial+epithelial+cell+growth+medium/pmc12270386-27-7-12
    Average 90 stars, based on 1 article reviews
    bronchial epithelial cell growth medium - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    bronchial epithelial cells  (PromoCell)
    95
    PromoCell bronchial epithelial cells
    Comparative histological analysis of xenografts and ALI cultures generated with mutant hBECs from the same donor. A. Representative H&E images of the <t>epithelial</t> structure of xenografts. Images were taken from areas that comprise surrounding mouse stroma, epithelial layer and lumen for xenografts with cystic structure. For solid xenografts, images were taken from areas that comprise surrounding mouse stroma and tumour nests. For TC+P and TC+PS mutants, representative images of areas with squamous and mucociliary morphologies are shown separately. L=Lumen; d= dyskeratosis. B. Representative H&E images of the epithelial structure of ALI cultures. C. Representative images of p63 immunohistochemical staining of xenografts. L=Lumen. D. Images depicting the presence of intercellular bridges and keratin pearls in TC+PKS mutants, two features of well-differentiated LUSC. Arrows mark the presence of intercellular bridges. kp= keratin pearl. E. TTF-1 immunohistochemical staining of a TC+PKS xenograft showing the absence of expression of this lung adenocarcinoma marker. F . Quantification of total invading single cells into the mouse stroma and an example image of an invading single cell stained for human mitochondria. Data shown as mean±SEM (n=6 xenografts). Adjusted p-values were calculated using one-way ANOVA followed by Tukey’s multiple comparisons test (only significant comparisons are shown) G. Images depicting a xenograft area with adjacent mucociliary and squamous morphology in a TC+PS mutant. Images show H&E staining, and immunohistochemical staining for mCherry, acetylated-tubulin and MUC5AC. Areas with mucociliary differentiation show expression of acetylated-tubulin (cilia) and MUC5AC (goblet cells). Mc=mucociliary; sq=squamous. Statistical significance shown as: ∗p < 0.05, ∗∗p < 0.01
    Bronchial Epithelial Cells, supplied by PromoCell, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/bronchial+epithelial+cell+growth+medium/Airway+Epithelial+Cell+Growth+Medium+Kit/bio_rxiv__2025__08__28__672595-201-4-20
    Average 95 stars, based on 1 article reviews
    bronchial epithelial cells - by Bioz Stars, 2026-10
    95/100 stars
    		  Buy from Supplier

    Image Search Results


    SARS-CoV-2 opsonized with CL-11 drives increased infectivity of respiratory epithelial cells. ( A and B ), Enhancement of BEAS-2B cell infection with SARS-CoV-2 variants pretreated with rCL-11 (0.1, 1.0, and 10.0 µg/mL) or media for 1 h at 37 °C. ( A ) England/02/2020 (MOI 0.005) and ( B ) B.1.617.2 (MOI 0.05). ( C and D ), Enhancement of Calu-3 cell infection with SARS-CoV-2 variants pretreated with rCL-11 (0.1, 1.0, and 10.0 µg/mL) or media for 1 h at 37 °C. ( C ) England/02/2020 (MOI 0.05) and ( D ) B.1.617.2 (MOI 0.05). Virus titers in the supernatant after 24 h determined by plaque assay. Data are pooled from two ( A , C , D ) or three ( B ) independent experiments and represent the mean ± SEM of triplicate or quadruplicate biological samples. Each group compared to 0 µg/mL rCL-11 by one-way ANOVA with Dunnett’s multiple comparison test, * P < 0.05, and *** P < 0.001. ( E and F ), Representative images of crystal violet stained plaque assay plates of BEAS-2B or Calu-3 cells infected with either England/02/2020 ( E ) or B.1.617.2 ( F ) or opsonized with 10 mg/mL rCL-11. ( G ) L-fucose inhibits the enhancement of SARS-CoV-2 (England/02/2020) infectivity driven by CL-11 in BEAS-2B cells. England/02/2020 (MOI 0.05) pretreated with media or with rCL-11 (10.0 µg/mL) in the presence or absence of L-fucose or D-galactose (1- or 10 mM final concentration) and virus titers determined as above. ( H ) Infectivity of SARS-CoV-2 (England/02/2020) opsonized with CL-11 is not inhibited by NHS. Quantification of SARS-CoV-2 England/02/2020 in the supernatant of BEAS-2B cells 24 h after infection with virus (MOI 0.005) pretreated with media or with rCL-11 (10.0 µg/mL) spiked with or without 10% NHS as detailed above. ( G and H ) Data are representative of two independent experiments with the mean ± SEM of five ( G ) and at least six ( H ) biological samples. ** P < 0.01 and *** P < 0.001 determined by one-way ANOVA with Tukey’s multiple comparison test.

    Journal: Proceedings of the National Academy of Sciences of the United States of America

    Article Title: Glycan recognition by collectin-11 drives SARS-CoV-2 infectivity and membrane injury of respiratory epithelial cells

    doi: 10.1073/pnas.2521209122

    Figure Lengend Snippet: SARS-CoV-2 opsonized with CL-11 drives increased infectivity of respiratory epithelial cells. ( A and B ), Enhancement of BEAS-2B cell infection with SARS-CoV-2 variants pretreated with rCL-11 (0.1, 1.0, and 10.0 µg/mL) or media for 1 h at 37 °C. ( A ) England/02/2020 (MOI 0.005) and ( B ) B.1.617.2 (MOI 0.05). ( C and D ), Enhancement of Calu-3 cell infection with SARS-CoV-2 variants pretreated with rCL-11 (0.1, 1.0, and 10.0 µg/mL) or media for 1 h at 37 °C. ( C ) England/02/2020 (MOI 0.05) and ( D ) B.1.617.2 (MOI 0.05). Virus titers in the supernatant after 24 h determined by plaque assay. Data are pooled from two ( A , C , D ) or three ( B ) independent experiments and represent the mean ± SEM of triplicate or quadruplicate biological samples. Each group compared to 0 µg/mL rCL-11 by one-way ANOVA with Dunnett’s multiple comparison test, * P < 0.05, and *** P < 0.001. ( E and F ), Representative images of crystal violet stained plaque assay plates of BEAS-2B or Calu-3 cells infected with either England/02/2020 ( E ) or B.1.617.2 ( F ) or opsonized with 10 mg/mL rCL-11. ( G ) L-fucose inhibits the enhancement of SARS-CoV-2 (England/02/2020) infectivity driven by CL-11 in BEAS-2B cells. England/02/2020 (MOI 0.05) pretreated with media or with rCL-11 (10.0 µg/mL) in the presence or absence of L-fucose or D-galactose (1- or 10 mM final concentration) and virus titers determined as above. ( H ) Infectivity of SARS-CoV-2 (England/02/2020) opsonized with CL-11 is not inhibited by NHS. Quantification of SARS-CoV-2 England/02/2020 in the supernatant of BEAS-2B cells 24 h after infection with virus (MOI 0.005) pretreated with media or with rCL-11 (10.0 µg/mL) spiked with or without 10% NHS as detailed above. ( G and H ) Data are representative of two independent experiments with the mean ± SEM of five ( G ) and at least six ( H ) biological samples. ** P < 0.01 and *** P < 0.001 determined by one-way ANOVA with Tukey’s multiple comparison test.

    Article Snippet: Donor 1: female, 62 y, Caucasian Donor 2: male, 71 y, Caucasian Donor 3: male, 62 y, Caucasian Cryopreserved HBECs from healthy donors obtained from Epithelix and PromoCell were expanded and then seeded (2.12 × 10 5 cells/cm 2 ) onto collagen coated (30 μg/mL) tranwells and cultured submerged in Bronchial Epithelial Cell Growth Medium (Promocell) until confluent.

    Techniques: Infection, Virus, Plaque Assay, Comparison, Staining, Concentration Assay

    miR-488-3p overexpression inhibits LSCC cell proliferation, migration, invasion and epithelial-mesenchymal transition. (A) Quantitative PCR analysis of miR-488-3p expression in LSCC cells transfected with miR-488-3p or NC mimics. (B) Cell Counting Kit-8 and (C) colony formation assays detected the proliferative ability of LSCC cells transfected with miR-488-3p or NC mimics. Transwell assays determined the (D) migration and (E) invasion of LSCC cells transfected with miR-488-3p or NC mimics. (F) Western blotting of the protein levels of E-cadherin, N-cadherin and vimentin. Cropped images represent different blots, but samples are from the same experiment and the blots were processed in parallel. Scale bars, 100 µ m. * P<0.05, ** P<0.01 and *** P<0.001. miR, microRNA; LSCC, laryngeal squamous cell carcinoma; NC, negative control.

    Journal: International Journal of Molecular Medicine

    Article Title: MEIS1-regulated miR-488-3p suppresses the malignant progression of laryngeal squamous cell carcinoma by targeting ACVR1C

    doi: 10.3892/ijmm.2025.5583

    Figure Lengend Snippet: miR-488-3p overexpression inhibits LSCC cell proliferation, migration, invasion and epithelial-mesenchymal transition. (A) Quantitative PCR analysis of miR-488-3p expression in LSCC cells transfected with miR-488-3p or NC mimics. (B) Cell Counting Kit-8 and (C) colony formation assays detected the proliferative ability of LSCC cells transfected with miR-488-3p or NC mimics. Transwell assays determined the (D) migration and (E) invasion of LSCC cells transfected with miR-488-3p or NC mimics. (F) Western blotting of the protein levels of E-cadherin, N-cadherin and vimentin. Cropped images represent different blots, but samples are from the same experiment and the blots were processed in parallel. Scale bars, 100 µ m. * P<0.05, ** P<0.01 and *** P<0.001. miR, microRNA; LSCC, laryngeal squamous cell carcinoma; NC, negative control.

    Article Snippet: FD-LSC-1 and 2BS cells were cultured in Bronchial Epithelial Cell Growth Medium (Lonza Group, Ltd.) and MEM (Procell Life Science &Technology Co., Ltd.) with 10% FBS, respectively.

    Techniques: Over Expression, Migration, Real-time Polymerase Chain Reaction, Expressing, Transfection, Cell Counting, Western Blot, Negative Control

    ACVR1C knockdown inhibits LSCC cell proliferation, migration, invasion and epithelial-mesenchymal transition. (A) Analysis of ACVR1C expression in RNA-seq data ( GSE127165 ). (B) Quantitative PCR and (C) western blot analysis of the mRNA and protein expression levels of ACVR1C in AMC-HN-8 and FD-LSC-1 cells transfected with si-ACVR1C-1 and 2 or si-NC. Cropped images represent different blots, but samples are from the same experiment and the blots were processed in parallel. (D) Cell Counting Kit-8 and (E) colony formation assays investigated the proliferative ability of LSCC cells transfected with si-ACVR1C or si-NC. In the Transwell assay, ACVR1C knockdown significantly suppressed the (F) migration and (G) invasion of LSCC cells. (H) Western blot analysis of the protein levels of E-cadherin, N-cadherin and vimentin in LSCC cells transfected with si-ACVR1C or si-NC. Cropped images represent different blots, but samples are from the same experiment and the blots were processed in parallel. Scale bar, 100 µ m. * P<0.05, ** P<0.01 and *** P<0.001. ACVR1C, activin A receptor type 1C; LSCC, laryngeal squamous cell carcinoma; NC, negative control; si, small interfering RNA.

    Journal: International Journal of Molecular Medicine

    Article Title: MEIS1-regulated miR-488-3p suppresses the malignant progression of laryngeal squamous cell carcinoma by targeting ACVR1C

    doi: 10.3892/ijmm.2025.5583

    Figure Lengend Snippet: ACVR1C knockdown inhibits LSCC cell proliferation, migration, invasion and epithelial-mesenchymal transition. (A) Analysis of ACVR1C expression in RNA-seq data ( GSE127165 ). (B) Quantitative PCR and (C) western blot analysis of the mRNA and protein expression levels of ACVR1C in AMC-HN-8 and FD-LSC-1 cells transfected with si-ACVR1C-1 and 2 or si-NC. Cropped images represent different blots, but samples are from the same experiment and the blots were processed in parallel. (D) Cell Counting Kit-8 and (E) colony formation assays investigated the proliferative ability of LSCC cells transfected with si-ACVR1C or si-NC. In the Transwell assay, ACVR1C knockdown significantly suppressed the (F) migration and (G) invasion of LSCC cells. (H) Western blot analysis of the protein levels of E-cadherin, N-cadherin and vimentin in LSCC cells transfected with si-ACVR1C or si-NC. Cropped images represent different blots, but samples are from the same experiment and the blots were processed in parallel. Scale bar, 100 µ m. * P<0.05, ** P<0.01 and *** P<0.001. ACVR1C, activin A receptor type 1C; LSCC, laryngeal squamous cell carcinoma; NC, negative control; si, small interfering RNA.

    Article Snippet: FD-LSC-1 and 2BS cells were cultured in Bronchial Epithelial Cell Growth Medium (Lonza Group, Ltd.) and MEM (Procell Life Science &Technology Co., Ltd.) with 10% FBS, respectively.

    Techniques: Knockdown, Migration, Expressing, RNA Sequencing, Real-time Polymerase Chain Reaction, Western Blot, Transfection, Cell Counting, Transwell Assay, Negative Control, Small Interfering RNA

    Comparative histological analysis of xenografts and ALI cultures generated with mutant hBECs from the same donor. A. Representative H&E images of the epithelial structure of xenografts. Images were taken from areas that comprise surrounding mouse stroma, epithelial layer and lumen for xenografts with cystic structure. For solid xenografts, images were taken from areas that comprise surrounding mouse stroma and tumour nests. For TC+P and TC+PS mutants, representative images of areas with squamous and mucociliary morphologies are shown separately. L=Lumen; d= dyskeratosis. B. Representative H&E images of the epithelial structure of ALI cultures. C. Representative images of p63 immunohistochemical staining of xenografts. L=Lumen. D. Images depicting the presence of intercellular bridges and keratin pearls in TC+PKS mutants, two features of well-differentiated LUSC. Arrows mark the presence of intercellular bridges. kp= keratin pearl. E. TTF-1 immunohistochemical staining of a TC+PKS xenograft showing the absence of expression of this lung adenocarcinoma marker. F . Quantification of total invading single cells into the mouse stroma and an example image of an invading single cell stained for human mitochondria. Data shown as mean±SEM (n=6 xenografts). Adjusted p-values were calculated using one-way ANOVA followed by Tukey’s multiple comparisons test (only significant comparisons are shown) G. Images depicting a xenograft area with adjacent mucociliary and squamous morphology in a TC+PS mutant. Images show H&E staining, and immunohistochemical staining for mCherry, acetylated-tubulin and MUC5AC. Areas with mucociliary differentiation show expression of acetylated-tubulin (cilia) and MUC5AC (goblet cells). Mc=mucociliary; sq=squamous. Statistical significance shown as: ∗p < 0.05, ∗∗p < 0.01

    Journal: bioRxiv

    Article Title: Studying a human genetic model of lung squamous cell carcinoma with organotypic cultures and xenografts uncovers distinct advantages of each system and implicates NOTCH1 loss in tumour development

    doi: 10.1101/2025.08.28.672595

    Figure Lengend Snippet: Comparative histological analysis of xenografts and ALI cultures generated with mutant hBECs from the same donor. A. Representative H&E images of the epithelial structure of xenografts. Images were taken from areas that comprise surrounding mouse stroma, epithelial layer and lumen for xenografts with cystic structure. For solid xenografts, images were taken from areas that comprise surrounding mouse stroma and tumour nests. For TC+P and TC+PS mutants, representative images of areas with squamous and mucociliary morphologies are shown separately. L=Lumen; d= dyskeratosis. B. Representative H&E images of the epithelial structure of ALI cultures. C. Representative images of p63 immunohistochemical staining of xenografts. L=Lumen. D. Images depicting the presence of intercellular bridges and keratin pearls in TC+PKS mutants, two features of well-differentiated LUSC. Arrows mark the presence of intercellular bridges. kp= keratin pearl. E. TTF-1 immunohistochemical staining of a TC+PKS xenograft showing the absence of expression of this lung adenocarcinoma marker. F . Quantification of total invading single cells into the mouse stroma and an example image of an invading single cell stained for human mitochondria. Data shown as mean±SEM (n=6 xenografts). Adjusted p-values were calculated using one-way ANOVA followed by Tukey’s multiple comparisons test (only significant comparisons are shown) G. Images depicting a xenograft area with adjacent mucociliary and squamous morphology in a TC+PS mutant. Images show H&E staining, and immunohistochemical staining for mCherry, acetylated-tubulin and MUC5AC. Areas with mucociliary differentiation show expression of acetylated-tubulin (cilia) and MUC5AC (goblet cells). Mc=mucociliary; sq=squamous. Statistical significance shown as: ∗p < 0.05, ∗∗p < 0.01

    Article Snippet: A total of 30,000 bronchial epithelial cells were pelleted and resuspended in 100 μl of Airway Epithelial Cell Growth Medium (PromoCell, C-21160), then seeded directly onto the collagen-coated membranes, which were placed in individual wells of a 24-well plate.

    Techniques: Generated, Mutagenesis, Immunohistochemical staining, Staining, Expressing, Marker